Product Description
Oxybutynin is an anticholinergic medication that is indicated in patients with overactive bladder or symptoms of detrusor overactivity, including urinary frequency and urgency. Oxybutynin is an anticholinergic medication that has antispasmodic activity against smooth muscle, including bladder smooth muscle. The active metabolite is N-desethyloxybutynin. It blocks the muscarinic effect of acetylcholine by competitively inhibiting the postganglionic muscarinic 1, 2, and 3 receptors. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK499985/)
Mechanisms of Action: MR Inhibitor,mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: VIATRIS & KG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, Korea
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Hyperhidrosis
Phase 2: Overactive Bladder|Sleep Apnea, Obstructive|Urinary Incontinence, Urge
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-000062-34 | P2 |
Active, not recruiting |
Sleep Apnea, Obstructive |
2025-04-11 |
|
| H-2310-153-1481 | P2 |
Not yet recruiting |
Overactive Bladder |
2025-04-01 |
|
| MedRing-04 | P2 |
Active, not recruiting |
Urinary Incontinence, Urge |
2023-03-28 |
|
| jRCT2031200143 | P3 |
Completed |
Hyperhidrosis |
2022-02-04 |